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Abstract Hematopoietic stem cell transplantation is asso-
ciated with a severe immune deficiency. As a result, the
patient is at high risk of infections. Innate immunity,
including epithelial barriers, monocytes, granulocytes, and
NK cells recovers within weeks after transplantation. By
contrast, adaptive immunity recovers much slower. B- and
T-cell counts normalize during the first months after
transplantation, but in particular, T-cell immunity may
remain impaired for years. During the last decade, much
of the underlying mechanisms have been identified. These
insights may provide new therapies to accelerate recovery.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is an
effective treatment for various hematological disorders.
Conditioning of the patient should ablate, or at least
strongly constrain host hematopoiesis to provide space for
engraftment and suppress the patient’s immune system to
prevent graft rejection. Although their intensity may vary
with the type of disease and the clinical condition of the
patients, most protocols destroy the patient’s immune
system almost completely. In addition, alloreactive donor
T cells cotransfused with the graft will eradicate the
remaining patient cells of hematopoietic origin so that the
patient’s immunity after transplant will have to come from
the transplanted donor cells.
After transplantation, monocytes are the first cells to
engraft, rapidly followed by granulocytes, platelets, and
natural killer (NK) cells. Clinical engraftment, the first day
that the number of granulocytes is >0.5 G/L (and remains
so for at least three consecutive days) usually occurs
between day 10 and 25 after transplantation. Thereafter,
the number of most leukocyte subsets normalizes rapidly
(Fig. 1). This repopulation of cells in the host restores much
of the innate immunity; antibacterial prophylaxis can be
lowered, and infection surveillance decreased when the
number of granulocytes has reached a critical threshold.
Judging the competence of the adaptive immune system
by the number of regenerated T- and B-cells would
however be a huge mistake. Although the number of
lymphocytes increases rapidly during the first months after
transplant, and the counts of most lymphocyte subsets
(except for CD4 T cells) reach normal values in a
considerable number of patients, the frequency of infections
remains extremely high (1–9). The reasons for this are
manifold. Most T cells present during the first year after
transplantation are progeny of the donor T cells co-
transfused with the graft that have expanded after entering
the patient’s “empty” T-cell compartment. Despite the fact
that the number of mature lymphocytes in the graft could be
theoretically sufficient to contain all the necessary antigen
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specificities, transfer of the donor’s immunity is poor.
Posttransplant, the conditions for lymphocyte activation in
the patient are very different compared to normal conditions
in which antigen, antigen-induced cytokines in secondary
lymphoid organs, interaction between lymphocytes with the
same antigen-specificity and available space are the key
parameters that determine the size of clones with a
particular specificity. During the first weeks, the high level
of inflammatory cytokines induced by the conditioning
(10–12) in combination with the available space that favors
homeostatic expansion of T cells changes the composition
of the transferred lymphocyte pool dramatically. The clonal
size of a limited number of T cells may grow extensively so
that the majority of the T cell pool contains only a few
antigen specificities (13–15). Most of the cells will have
lost the necessary homing receptors to enter secondary
lymphoid organs to interact with antigen-presenting cells
and stimulate B cells. The latter disappear almost com-
pletely from the circulation and are replenished after 2–
3 months (Fig. 1; 8, 16–18). However, even if the B-cell
repertoire is restored relatively fast, antibody responses will
be hampered by the lack of T-cell help and will either be
absent or, at best, resemble primary B cell responses (16,
19–23).
T- and B-cell responses will be incomplete for a long
period after transplantation. Restoration of the T-cell
compartment is prerequisite for functional immune recov-
ery and at the same time is most cumbersome, in particular,
in the elderly patient (24–26). Here, we will discuss the
reconstitution of the patient’s immunity for each part of the
immune system separately. Early after transplant denotes in
the first 3 months while late after transplant denotes after
6 months.
Nonhematological cells of the immune system
The first defense against infections consists of physical
barriers such as the skin. Radiation, chemotherapy, or acute
graft-versus-host disease (GVHD)-induced damage to the
skin, the respiratory and digestive mucosa increases the
chance of pathogen penetration into the patient early
posttransplant. Late posttransplant, the epithelium is healed;
the volume of protective secretions (e.g., tears or saliva)
Fig. 1 Recovery of leukocyte
subsets. All horizontal axes dis-
play days posttransplant. Patient
medians (diamonds) and 25th–
75th percentiles (error bars) are
shown. Normal medians are in-
dicated by the dashed horizontal
lines (neutrophils not available).
The thick horizontal lines denote
the normal fifth and 95th per-
centiles (neutrophils 2.5th and
97.5th percentiles). Pretrans-
plant studies are arbitrarily
shown as day −100. Reproduced
from [92] with permission
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become gradually normal in patients without chronic
GVHD but often continues to be subnormal in those with
chronic GVHD (27). There is typically no deficiency of
serum complement, which is mainly produced by hepato-
cytes (28). Hence, physical barriers such as skin and serum
proteins that play a role in the defense against pathogens
usually recover rapidly in patients without severe GVHD.
However, serum protein deficiencies that were asymptom-
atic before transplantation may become clinically manifest
after transplant and be at the origin of severe infections
(29).
Phagocytes and antigen-presenting cells
Neutrophil counts usually become normal by approximately
2 weeks after G-CSF mobilized blood stem cell grafting,
3 weeks after bone marrow grafting and 4 weeks after cord
blood grafting (30). Neutrophil function (e.g., chemotaxis,
phagocytosis, superoxide production, and killing of bacte-
ria) early posttransplant may be subnormal, particularly in
patients with acute GVHD. Neutrophil function may remain
subnormal in patients with chronic GVHD (31). This could
reflect the negative effect of corticosteroids (used for
GVHD treatment) on neutrophil function.
Monocyte counts normalize by 1 month posttransplant
(30). Macrophages are relatively chemo/radioresistant, so
their numbers do not drop substantially; recipient macro-
phages are gradually replaced with donor macrophages
over several months posttransplant (32). The first mono-
cytes in the circulation are produced by the transplanted
HSC (33). G-CSF mobilized PBSC grafts contain a large
number of monocytes [approximately two logs more than
marrow grafts (8)] but most of the monocytes infused with
PBSCs probably either die or become tissue macrophages
within days because monocytes in the blood of PBSC
recipients become virtually undetectable by day 7 (Storek,
unpublished). The function (e.g., IL-1 production or antigen
presentation) of the recovering monocytes may be subnor-
mal for approximately a year (34, 35), though several
studies suggest normal function already early posttransplant
(36–38).
Dendritic cells can be subdivided into at least five
categories according to their location: (1) epithelial den-
dritic cells that migrate to the extrafollicular areas of lymph
nodes upon encounter of antigen, (2) dendritic cells in the
extrafollicular areas of lymph nodes and spleen, whose
main function is to present antigen to T cells and provide
costimulatory signals, (3) blood dendritic cells, which may
represent the precursors of dendritic cells in the epithelium
and the extrafollicular areas of spleen/lymph nodes, (4)
thymic dendritic cells that play a role in deletion of
autoreactive T cells, and (5) follicular dendritic cells in
the germinal centers of lymph nodes and spleen that play a
role in the maturation of the B cell (generation of
somatically mutated and IgD/IgM→IgG/IgA/IgE-switched
B cells).
Langerhans cells (epithelial dendritic cells in the skin)
are low in number early posttransplant and near-normal by
6 months posttransplant (39). Dendritic cells in the
extrafollicular areas of lymph nodes are present in about
one third of transplant recipients, but a well-organized
structure of follicles and germinal centers in lymph nodes
and spleen is seldom observed during the first 6 months
after transplantation (40–42). The grafted HSC produce
blood dendritic cells detectable at 2–3 weeks (33) that
remain low in quantity in the first 3 months posttransplant
(Fig. 1); subsequently, counts of DC1 (conventional or
myeloid dendritic cells, CD11c+) tend to normalize
whereas counts of DC2 (plasmacytoid dendritic cells,
CD123+) are low even at 1 year posttransplant (12, 43,
44). Thymic dendritic cells appear in the thymus within
weeks posttransplant in mice (45); the recovery of these
cells in humans has not been studied. Follicular dendritic
cells appear to recover extremely slowly—even at 1 year
after grafting, these cells appear sparse (40, 46). This could
explain why germinal centers appear only late posttrans-
plant (40–42, 46) and the reconstitution of memory B cells
is slow (47).
Recipient epithelial dendritic cells may be important for
the pathogenesis of GVHD because they will efficiently
prime the alloreactive T cells in the graft. In mice, skin
GVHD occurred in the presence but not in the absence of
recipient Langerhans cells (48). In man, recipient Langer-
hans cells are present early after transplant (39), but it is not
formally proven that these cells initiate GVHD of the skin.
NK cells
NK-cells counts as well as NK cell in vitro cytotoxicity
recover during the first weeks after transplantation (8, 12,
17, 49–52). The number of NK cells is supranormal during
1–3 months posttransplant (Fig. 1) and, consistent with
their role in defense against herpes viruses (53, 54), this
phenomenon is more pronounced in cytomegalovirus-
positive recipients (49, 55). The phenotype of the NK cells
repopulating the patient is different from that in normal
individuals (12, 50, 52, 56–59). The hallmark is the
overrepresentation of CD56highCD16− cells that produce
more IFN-γ and are less cytotoxic than NK cells in normal
individuals (12, 50, 52, 56). The classical view has been
that these cells are immature precursors of CD56dimCD16+
cytotoxic NK-cells representing the major population in the
peripheral blood of normal individuals. However, pheno-
types of NK cells change rapidly when stimulated by
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cytokines such as IL-2, IL-12, and IL-15 (60, 61), and it
cannot be excluded that the IL-15 rich cytokine milieu
posttransplant (12, 58, 59) is the major cause of the unusual
phenotypes observed.
Recently, the characteristics of NK cells that repopulate
the patients have received much interest. During the first
months after transplantation, NK cells kill target cells
without ligands for their killer cell immunoglobulin
receptors inhibitory (KIR) more efficiently (62). As a
result, NK cells may have a significant antileukemic effect,
in particular, against AML (63–65). This effect is clinically
most relevant in patients lacking KIR ligands present in the
(haploidentical) HSC donor but may be present more
generally (reviewed in (66)). Such alloreactive NK cells
may also have a beneficial effect because they eliminate
host APC that prime alloreactive T cells causing GVHD
(63). This topic will be reviewed in more detail in the
contribution of A. Velardi and colleagues in this issue of
Springer seminars in Immunopathology.
T cells
A blood count is generally the first test performed when a
patient shows signs of an immune deficiency. This test is
often informative because many clinical symptoms can
simply be attributed to a low number of a particular
leukocyte subset. During the first years of clinical trans-
plantation, it was not well understood why after HSCT the
number of T cells does not correlate well with infections.
Only after the advent of lymphocyte-subset specific
monoclonal antibodies, it became clear that during the first
year after transplantation, the T-cell compartment was
abnormal and contained many activated (HLA-DR+) cells
and considerably more CD8+ and much less naïve T cells
than in normal individuals (17, 67–69). Furthermore,
responses to mitogenic stimuli in vitro were decreased
(69–71) and in vitro responses to recall antigens were
virtually absent (70, 72).
Although these long-lasting alterations may explain why
the patient’s T-cell immunity remained deficient for a
prolonged period and vaccinations were ineffective during
the first year, the underlying mechanism remained unclear.
Mackall and Gress demonstrated that the human T cell
compartment is repopulated after intensive chemotherapy
by two different pathways (24, 73). One is similar to ontogeny
when thymic emigrants replenish the T-cell compartment
and depends therefore on a functioning thymus. In addition,
the T-cell compartment can be repopulated through periph-
eral expansion of mature T cells. The latter pathway is
predominant when the thymic activity is low (74), which is
likely to be the case in adult patients. Several publications
(72, 75–78) followed showing that, not unexpectedly, the
situation was even more radical after HSCT. This has been
demonstrated most intelligibly in patients conditioned with
total body irradiation and cyclophosphamide and trans-
planted with an in vitro T-cell depleted allogeneic HSC
graft. The infusion of very low numbers of donor cells into
these patients had two consequences. First, the lack of
alloreactivity allowed the few recipient T cells not
eliminated by the conditioning to survive. Because the
conditioning destroys the patient’s HSC (79), every T cell
of patient origin after transplantation must be the progeny
of the few T cells present at transplant, and the increase of
T cells must therefore be the result of expansion. Second,
the number of donor T cells co-infused with the graft is so
low that, during the first 2 weeks, the T-cell compartment is
virtually empty. This induces a rapid parallel expansion of
donor and recipient T cells that reconstitute the T cell
compartment before the appearance of the first donor-
derived naive T cells produced by the thymus (78). The
latter can be easily monitored because, under these
conditions, the T-cell compartment that has been reconsti-
tuted by expansion uniquely, comprises only T cells that
express memory markers. Rufer has described a patient
transplanted with a T-cell depleted bone marrow from a
donor with CD4+ memory T cells expressing high amounts
of CD45RA, the isoform of CD45 expressed by naïve cells
that is downregulated upon activation. This phenotype
without apparent functional consequences is present in ~1%
of the population and is caused by a point mutation in the
exon A of CD45 that leads to an abnormal splicing pattern
(80). This allowed direct visualization of the entire process
(81) because patient (CD45RA−RO+) and donor
(CD45RAbrightRO+) memory/effector CD4+ T cells could
be discriminated by flow cytometry. Naïve (CD45RA+RO−)
T cells appeared after approximately 6 months and were
entirely of donor origin. The thymus independent pool of
patient T cells predominated during the first years and
persisted for more than 7 years. The size of the pool of
donor memory/effector increased, most likely because
ongoing immune responses recruited cells from the naïve
T-cell pool produced by the thymus (81). This pattern of
reconstitution is representative for patients after depletion
of the mature T cell pool. In adults, naïve T cells do not
emerge during the first 4 months, and partial restoration of
the naïve T cell pool may require 1 to 2 years and may only
occur in individuals younger than 45–50 years (24, 72, 78,
82).
Repopulation of the posttransplant T-cell compartment
by expansion is the consequence of natural homeostatic
mechanisms that control the size of the T-cell pool. In
normal individuals, T cells compete for available space
through competition for homeostatic cytokines such as IL-7
and IL-15 that are produced by cells of nonhematological
origin. Triggering of the T-cell receptor by antigen
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increases the T cell’s “competitiveness” so that new
memory cells can enter the memory pool without increasing
its size because they replace less competitive cells (83).
After transplantation, IL-7 and IL-15 are produced but not
instantly consumed, which results in supranormal serum
levels of these homeostatic cytokines (11, 12). The amounts
of IL-7 and IL-15 produced to maintain a complete naïve
and memory T-cell compartment are available to the few T
cells present after transplantation; these will expand until
they reach a number that is in the range of that of the
memory pool in normal individuals. Although homeostatic
expansion also occurs when T cells are triggered by self-
peptides (83, 84), and therefore is not strictly antigen-
dependent, the presence of antigen favors proliferation to
such an extent that initially, the T-cell compartment is filled
up mainly by cells that recognize the antigens present in the
host at the moment of transplant (85). As a result, large
parts of the T-cell repertoire after transplantation may be
directed against mismatched histocompatibility antigens
(14, 86, 87) or against herpes viruses (88–91) that are
present in the majority of patients at the moment of
transplant while other specificities may be lost completely
(85).
The fact that after transplantation the T-cell compartment
is reconstituted through homeostasis based on the rules
described above is able to explain many of the phenomena
that have been reported since the start of clinical transplan-
tation. The abundance of cells with activated phenotypes
(17, 67–69), the high percentage of cells in cell cycle (92),
and the rapid shortening of telomeres in T cells (93, 94)
during the first months reflect the initial repopulation by
expansion. The lack of correlation between the number of
CD8+ T cells after transplantation and the wide (2–3 log)
range of CD8+ T cells infused (8, 51, 95) illustrates the
remarkable potential of mature T cells to repopulate the
periphery until a particular number is reached. The inversed
CD4/CD8 ratio (Fig. 1), much more prominent in cyto-
megalovirus-positive patients (96, 97) and in patients
suffering from GvHD (67) shows that repopulation by
expansion is driven by antigen. Furthermore, because these
cells can only be recruited from the few T cells present at
transplant, their T-cell receptors may dominate the entire
repertoire (13–15, 98). The paucity of naïve T cells early
after transplant emphasizes the initial insignificance of the
thymic pathway while the kinetics of their recovery, much
slower in adults than in children (25, 75, 78, 99) reflects
the inefficiency of the posttransplant thymic rebound.
Repopulation of the T-cell compartment by homeostatic
expansion does not restore T-cell immunity. Although the
frequency of infections decreases considerably after the
innate immune system has recovered, patients remain at
high risk during the first 2 years posttransplant and suffer
considerably more from infectious morbidity than their age-
matched controls. Late posttransplant and in the absence of
GVHD, infections are less frequent (though still more
frequent than in healthy individuals), and the predominant
pathogens are viruses (1, 3, 4, 6, 7, 9). Furthermore,
responses to vaccinations during the first year are low or
completely absent (9, 100–102).
Posttransplant T-cell immune deficiency is caused by the
destruction of the patient’s T cells, by the lack of efficient
transfer of donor immunity and by the incapacity of the
thymus to produce sufficient numbers of naïve T cells. The
latter is not only owed to the decreased thymic function in
adults but also to the damage inflicted by the conditioning
and by donor alloreactive donor T cells transferred with the
graft. As a consequence, variables such as the treatment of
the graft, the intensity of the conditioning, the occurrence of
GVHD and the age of the recipient are significantly
correlated with the recovery of the patient’s immunity.
The posttransplant immunity is entirely of donor origin
unless the conditioning and/or the manipulation of the graft
strongly favor the survival of recipient T cells (91, 103).
The extent of transferred immunity and the significance
thereof is controversial. There are many studies describing
the transfer of T- or B-cell immunity (4, 91, 104–108).
After boosting the donor in the weeks before transplanta-
tion with tetanus toxoid or with Haemophilus influenzae
polysaccharide–protein conjugate, specific antibody is
found in the patient (104, 105, 108, 109). However, it is
not clear to what extent the antigen-specific antibody
production may be attributed to aspecific triggering of the
transferred B cells, a phenomenon frequently observed after
transplantation (110). Sustained antibody production does
require encounter with antigen (100, 111) and, for most
antigens, T-cell help.
T-cell immunity against poliovirus, tetanus, diphtheria,
and measles is lost after transplantation (2, 104, 112).
Interestingly, CMV- or EBV-specific T-cells are readily
detected early after transplant (3, 4, 88, 89, 91, 113),
usually at much higher frequencies (up to 25% of the CD8 +
T cells) than in normal individuals (91, 113). The key
difference is the presence of antigen that triggers a supra-
normal expansion of T cells encountering antigen under
lymphopenic conditions (85). As a result, transferred
immunity against the antigens present at the moment of
transplant persists, while other specificities are lost. The
latter may simply be the result of the homeostatic
competition of T cells triggered by antigen. Another
explanation could be that after transplantation, transferred
T cells lose the homing receptors requisite to circulate
through lymph nodes so that they cannot be primed by
antigen presented by DC.
If donor immunity is preserved more efficiently in the
presence of antigen at the onset of homeostatic expansion,
very early immunizations might be effective. Two studies
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reported that vaccination with H. influenzae polysaccha-
ride–protein conjugate or tetanus toxoid of the patient
shortly before transplantation enhanced responses to vacci-
nations with the same antigen at 2–3 months posttransplant
(108, 114), a time point at which patients usually do not
respond at all (100, 101, 108). Although the rise in
antibody titers obtained were modest, these encouraging
data may warrant further study.
It is notable that T-cell depletion of the graft interferes
less with the transfer of immunity than would have been
expected on the basis of the number of T cells transferred
(4, 91, 106, 107, 115). Although after T-cell depletion, the
T-cell receptor repertoire is more limited (15, 76), several
studies show that the number of T cells specific for CMV,
EBV, Candida (i.e. the antigens commonly present) are
comparable in recipients of unmanipulated or T-cell-
depleted grafts (4, 91, 106, 107). Functional immunity
early posttransplant may not be significantly lower in
recipients of T-cell depleted grafts (104, 116–120). Poten-
tial explanations for this include the possibility that the
number of antigen-specific T cells transferred is not of great
importance since the expansion potential of T cells in the
presence of antigen is sufficient, or perhaps more impor-
tantly, that after T-cell depletion, immunological reconsti-
tution is less often impaired by GVHD or its prophylaxis/
treatment than in recipients of unmanipulated grafts.
Once the T-cell compartment has been reconstituted by
expansion and many antigen-specificities have been lost, a
complete T-cell repertoire can only come from naïve T cells
produced by the thymus (72, 75, 121). Reconstitution does
not occur in thymectomized patients (122) and is less
efficient in elderly patients or in patients who have suffered
from GVHD (24–26, 75, 78, 123, 124). This clearly
illustrates the diminishing capacity of the adult thymus to
produce T cells and the thymic damage inflicted by GVHD
(see also the contribution by W. Krenger in this issue of
Springer Seminars in Immunopathology). Measuring the
thymic rebound may thus be helpful to determine the
optimal time to start the revaccination (72).
B cells
B cells are low in number or undetectable during the first
2 months after marrow grafting (reviewed in (18)). They
subsequently increase, and blood B cell counts often
become supranormal by 1–2 years after grafting. The rise
is faster in autologous than allogeneic marrow recipients. It
is faster in patients without GVHD than in those with
GVHD (16, 55), probably because GVHD and/or its
treatment hamper B-lymphopoiesis (125, 126).
During the first 1–2 years posttransplant, memory B
cells are scarce (Fig. 1). Most B cells are naïve (membrane
IgDhigh, membrane IgMhigh) (18), lack somatically mutated
VDJ genes (19–21), and produce IgM rather than IgG or
IgA (16, 22, 23). After an initial fall early posttransplant,
serum isotype levels recover in the same sequence as in
young children: IgM → IgG1/IgG3 → IgG2/IgG4/IgA
(127). Hence, B cell reconstitution after HSCT resembles a
recapitulation of ontogeny that is likely to occur more
slowly than in young children because follicular dendritic
cells and CD4 T cells in germinal centers needed for
isotype switching are scarce. It is noticeable that total
(isotype) immunoglobulin levels are imperfect markers of
posttransplant humoral immunity since many of the anti-
bodies produced may be autoantibodies or mono/oligoclo-
nal antibodies of irrelevant specificity rather than specific
for infectious agents (110). Antibodies with a relevant
specificity usually fall early posttransplant. The magnitude
of the decrease is substantial after allogeneic HSCT;
however, it is only minor (or undetectable) after autologous
HSCT. Subsequent to that, the levels of antibodies with
relevant specificities depend on the posttransplant encoun-
ter of the antigen. Without encounter of the antigen, the
levels of pathogen-specific antibodies become gradually
undetectable, often over a course of years (128). If the
encounter of the antigen occurs (e.g., CMV in patients that
were CMV-seropositive pretransplant) the levels of CMV-
specific antibodies normalize within about 1 year—earlier
in patients with and later in patients without immune
donors (129, 130). This is only true for protein antigens. In
the case of polysaccharide antigens (e.g., pneumococcal
capsular polysaccharides), the levels of specific antibodies
may normalize only very late (2–20 years after transplant)
even if the encounter of the antigen is likely (131, 132).
Antibody response to vaccination is another measure of
B cell immunity. Early posttransplant, responses to any
antigen are subnormal. Responses to protein antigens
recover faster (usually within 1–2 years) than responses to
polysaccharide antigens (usually at ≥2 years posttrans-
plant). Responses to protein recall antigens (e.g., poliovirus
or tetanus toxoid) tend to recover faster than responses to
protein neo-antigens. The recovery of antibody responses to
any antigen is delayed in patients with chronic GVHD
(reviewed in (133)). T-cell depletion of the graft or
posttransplant treatment with anti-T-cell antibodies may
delay the recovery of antibody responses (134). Also, the
responses may recover faster in young versus old individ-
uals (134), which could be related to the faster recovery of
CD4 T cells in younger patients.
Are post-allotransplant B cells and plasma cells of donor
or recipient origin? Virtually all circulating B cells are of
donor origin after T cell replete grafting with high intensity
conditioning; after T-cell-depleted transplantation and after
transplantation with low intensity or no conditioning, a
variable degree of incomplete chimerism of B cells is
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frequently established (reviewed in (133)). Antibodies are
primarily of recipient origin early posttransplant; even in
patients with complete chimerism of lymphocytes, the
conversion to only donor-type antibodies takes months or
years (reviewed in (133)). This is likely due to the relative
radioresistance and longevity of recipient plasma cells (135,
136) and the lack of B cells early posttransplant.
Do posttransplant B cells originate from the B cells
infused with the graft or from the infused stem cells? This
has not been determined conclusively. Antigen-specific
antibody production can be adoptively transferred from
immune donors with T-cell-depleted grafts (107). Recipi-
ents of blood stem cell grafts that contain 18 times more B
cells than marrow grafts have higher B cell counts in the
first 3 months posttransplant compared to marrow graft
recipients (8). This suggests that early posttransplant, the
infused B cells contribute to the recipient B cell pool.
However, there is also indirect evidence for the origin of B
cells from stem cells, as supranormal amounts of B-cell
precursors are frequently found in the marrow at 2–
12 months after transplant, i.e., prior to the overshoot of
circulating B cell counts above the normal adult range (125,
137–139), and in recipients of B cell-purged autologous
marrow, the tempo of B-cell reconstitution is not slower
than in the recipients of unmanipulated marrow (140–142).
Thus, both B-cell-derived and stem-cell-derived B cells
may coexist after grafting. The B cells derived from infused
B cells may predominate early, whereas the stem cell-
derived B cells probably predominate late posttransplant.
What could be done to increase posttransplant
immunity?
As T-lymphocytopenia appears to be an important cause of
posttransplant infectious diseases, especially due to herpes-
viruses, research to improve T-cell restoration after grafting
is ongoing. This can be achieved by (1) infusing mature T
cells from the donor to the recipient or (2) stimulating
recipient de novo T-cell production (thymopoiesis)—(1)
Infusion of a high number of T cells from the donor may
reduce the frequency of infections (8) but is associated with
an unacceptably high risk of GVHD (143). Infusion of
virus-specific T cells decreases the incidence of viral
infections without increasing the incidence of GVHD
(144–151). It is likely that this will enter clinical practice
when manufacturing of virus-specific T cells has been
simplified. An alternative approach under investigation is
the infusion of T cells depleted of T cells reactive to host
alloantigens (152–154). (2) Stimulation of thymopoiesis is
attractive, as it should theoretically restore a broad T-cell
repertoire, including against pathogens present in the
recipient (155, 156). In mice, the following strategies have
yielded improved thymopoiesis: (1) interleukin-7 (IL-7)
administration (157–160), (2) growth hormone administra-
tion (161), and (3) protection of thymic epithelium from
conditioning- or GVHD-induced damage by keratinocyte
growth factor (KGF) administration (162, 163). Whether
these approaches can enhance thymopoiesis in primates is
controversial. IL-7 administration to monkeys resulted in
increased T cell counts in four studies (164–167); however,
in three of these studies, this was purely due to increased T-
cell proliferation and not increased thymopoiesis (164–
166). In the only study of IL-7 in human reported so far,
IL-7 administration increased T-cell counts primarily or
entirely due to increased T-cell proliferation; potential
contribution of increased thymopoiesis was unlikely as the
increase of T-cell receptor excision circle-containing T-cell
counts was insignificant and unrelated to patient age, and
by computer tomography, there was no thymic enlargement
(156). Growth hormone effect on thymopoiesis in primates
has not been studied. KGF given to macaques to protect the
thymus from radiation damage resulted in only mild and
inconsistent improvement of thymopoiesis (168).
HSCT is often the best chance of curing several forms of
hematological malignancies and of congenital immune
deficiencies. An at least transient immune deficiency is
one of the side effects that seems unavoidable given the fact
that an intense immunosuppressive conditioning must be
given to allow engraftment. More research is needed but in
the next future, a combination of the strategies mentioned
above may improve posttransplant immunity considerably.
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